1Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: Part I. J Am Acad Dermatol 2007; 56: 353–70.
10.1016/j.jaad.2006.05.069
PubMed Web of Science® Google Scholar
2Legiehn GM, Heran MK. Venous malformations: classification, development, diagnosis, and interventional radiologic management. Radiol Clin North Am 2008; 46: 545–97, vi.
10.1016/j.rcl.2008.02.008
PubMed Web of Science® Google Scholar
3Marler JJ, Mulliken JB. Vascular anomalies: classification, diagnosis, and natural history. Facial Plast Surg Clin North Am 2001; 9: 495–504.
CAS PubMed Google Scholar
4North PE, Mihm MC Jr. Histopathological diagnosis of infantile hemangiomas and vascular malformations. Facial Plast Surg Clin North Am 2001; 9: 505–24.
CAS PubMed Google Scholar
5Hill RA, Pho RW, Kumar VP. Resection of vascular malformations. J Hand Surg Br 1993; 18: 17–21.
10.1016/0266-7681(93)90187-K
CAS PubMed Web of Science® Google Scholar
6Ren JG, Chen G, Zhu JY et al. Downregulation of the transforming growth factor-β/connective tissue growth factor 2 signalling pathway in venous malformations: its target potential for sclerotherapy. Br J Dermatol 2014; 171: 242–51.
10.1111/bjd.12977
CAS PubMed Web of Science® Google Scholar
7Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62–4.
10.1016/S0140-6736(03)15172-0
CAS PubMed Web of Science® Google Scholar
8Jun JI, Lau LF. Taking aim at the extracellular matrix: CCN proteins as emerging therapeutic targets. Nat Rev Drug Discov 2011; 10: 945–63.
10.1038/nrd3599
CAS PubMed Web of Science® Google Scholar
9Hall-Glenn F, De Young RA, Huang BL et al. CCN2/connective tissue growth factor is essential for pericyte adhesion and endothelial basement membrane formation during angiogenesis. PLOS ONE 2012; 7: e30562.
10.1371/journal.pone.0030562
CAS PubMed Web of Science® Google Scholar
10Lipson KE, Wong C, Teng Y, Spong S. CTGF is a central mediator of tissue remodeling and fibrosis and its inhibition can reverse the process of fibrosis. Fibrogenesis Tissue Repair 2012; 5 (Suppl. 1): S24.
10.1186/1755-1536-5-S1-S24
PubMed Google Scholar
11Jin Y, Lin X, Li W et al. Sclerotherapy after embolization of draining vein: a safe treatment method for venous malformations. J Vasc Surg 2008; 47: 1292–9.
10.1016/j.jvs.2008.01.010
PubMed Web of Science® Google Scholar
12Spence J, Krings T, TerBrugge KG, Agid R. Percutaneous treatment of facial venous malformations: a matched comparison of alcohol and bleomycin sclerotherapy. Head Neck 2011; 33: 125–30.
10.1002/hed.21410
PubMed Web of Science® Google Scholar
13Yang Y, Sun M, Ma Q et al. Bleomycin A5 sclerotherapy for cervicofacial lymphatic malformations. J Vasc Surg 2011; 53: 150–5.
10.1016/j.jvs.2010.07.019
PubMed Web of Science® Google Scholar

Volume171, Issue2

August 2014

Pages 209-210

Profibrotic agents for venous malformations?

Abstract

References

References

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Profibrotic agents for venous malformations?

Abstract

References

References

Related

Information